XOMAP XOMA CORP 8.625% CUM PERP PFD SER A
- 25.450
- -0.040-0.16%
XOMA CORP 8.625% CUM PERP PFD SER A News
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of Its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc.,
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual
10-Q: Quarterly report
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (Tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or
XOMA Corporation Announces Closing of Tender Offer
XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On April 2nd, 2024 With 0.53906 USD Dividend Per Share
March 22nd - $XOMA CORP 8.625% CUM PERP PFD SER A(XOMAP.US)$ is trading ex-dividend on April 2nd, 2024. Shareholders of record on April 3rd, 2024 will receive 0.53906 USD dividend per share on Apr
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma
XOMA to Present at Upcoming Investor Conferences in March
EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor
XOMA Enters Into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per
Express News | Trading Halt: Halted at 7:55:00 A.m. ET - Trading Halt: Halt News Pending
XOMA Expands Its Commercial Royalty and Milestone Portfolio With DSUVIA Acquisition
XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration's (FDA) acceptance of Zevra
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive
XOMA Announces Stock Repurchase Program of up to $50 Million
EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA's first stock repurchase program, which
XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On January 2nd, 2024 With 0.53906 USD Dividend Per Share
December 21st - $XOMA CORP 8.625% CUM PERP PFD SER A(XOMAP.US)$ is trading ex-dividend on January 2nd, 2024. Shareholders of record on January 3rd, 2024 will receive 0.53906 USD dividend per share
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing From Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties
Low-cost financing capitalizes on XOMA's $14 million acquisition of VABYSMO (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (PLGG)
EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug
XOMA CORP 8.625% CUM PERP PFD SER A To Go Ex-Dividend On October 4th, 2023 With 0.53906 USD Dividend Per Share
September 26th - $XOMA CORP 8.625% CUM PERP PFD SER A(XOMAP.US)$ is trading ex-dividend on October 4th, 2023. Shareholders of record on October 5th, 2023 will receive 0.53906 USD dividend per shar
Analysis
Price Target
No Data
